Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Clinical trial NCT06787612 · RECRUITING

Trial details

NCT number: NCT06787612
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Start date: 2025-05-28
Primary completion: 2028-06-30
Enrollment: 297

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.